Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination With Vorinostat in KRAS-Mutant Colorectal Cancer Models
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-11-1507
Full Text
Open PDFAbstract
Available in full text
Date
December 15, 2011
Authors
Publisher
American Association for Cancer Research (AACR)